2,3-diphosphoglycerate and glycosylated hemoglobin in diabetes mellitus

Large amounts of intraerythrocyte 2-3 diphosphoglycerate (2-3 DPG) increase red cell oxygen-releasing capacity. Since glycosylated hemoglobins, found in higher percentages in diabetics, have an increased oxygen affinity, 2-3 DPG concentration was assayed in 12 diabetics (4 I.D.D., 8 N.I.D.D.) and 18 healthy volunteers. 2-3 DPG was related to glycemic fasting values and to glycosylated hemoglobins to evaluate if 2-3 DPG levels increase in diabetics as a compensatory mechanism to prevent peripheral hypoxia. 2-3 DPG values were significantly higher in diabetics than in normals: 11.4 mumol/gHb +/- 1.7 (= M +/- 1 SD) vs 9.8 mumol/gHb +/- 2.3 (p less than 0.05). 2-3 DPG did not correlate significantly to glycosylated hemoglobins or to glycemic values neither in diabetics nor in normals. These preliminary observations emphasize the usefullness of 2-3 DPG assay in evaluating peripheral oxygenation in diabetics: 2-3 DPG is higher in diabetics but does not correlate to glycemic equilibrium.     

Erythrocyte 2,3-diphosphoglycerate concentration before and after a marathon in men

Erythrocyte 2,3-diphosphoglycerate (2,3-DPG) concentration was studied in 23 runners before and after a marathon race. Blood samples were drawn from an antecubital vein the morning before the race (baseline), at 3 p.m. 2 h before the start, on finishing, and 12 and 36 h later. Compared to the baseline values, erythrocyte 2,3-DPG concentration was increased (p less than 0.001) immediately after the marathon from 4.62 +/- 0.14 to 5.56 +/- 0.13 mumol.ml-1 RBC and remained elevated 12 h later (5.45 +/- 0.14 mumol.ml-1 RBC): it returned to prerace values 36 h after completion of the marathon.     

Erythrocyte isozymes of phosphofructokinase in genetically high- and low-2,3-diphosphoglycerate rats

A major locus (Dpg) with two alleles (d and D) controls erythrocyte 2,3-diphosphoglycerate (DPG) levels in Long-Evans rats and is closely linked to a locus (Hbb) determining a hemoglobin electrophoretic polymorphism. Glycolytic intermediate levels and phosphofructokinase (PFK) kinetic studies suggest that in vivo PFK activity differences underlie the differences in DPG levels. We report here chromatographic and immunologic evidence that rat erythrocyte PFK is composed of two isozymes which elute from DEAE-Sephadex at positions identical to those of the isozymes in platelets and liver, respectively. The percentage of platelet-type PFK is significantly (P less than 0.05) smaller in low-DPG (dd) hemolysates than in DD hemolysates regardless of hemoglobin phenotype. When hemolysates were prepared in a stabilizing buffer, PFK specific activity was significantly (P less than 0.005) higher in DD rats. These data suggest that the PFK kinetic differences may result from alterations in the isozyme composition of active PFK.     

What is the best method to remove 2,3-diphosphoglycerate from hemoglobin?

We have compared the efficiency of four methods to remove 2,3-diphosphoglycerate (DPG) from hemoglobin (Hb), comprising dialysis, repeated ultrafiltration, gel filtration, and ion-exchange chromatography. All the methods eventually yielded hemoglobin solutions with a ratio of <0.002 mol of DPG/mol of Hb₄ and identical oxygen-binding properties but differed with respect to duration and versatility. Considering these factors, we found the combination of an ion-retardation resin and a mixed-bed resin to be most satisfactory.     

Enzymatic degradation of cyclic 2,3-diphosphoglycerate to 2,3-diphosphoglycerate in Methanobacterium thermoautotrophicum.

2,3-Diphosphoglycerate (2,3-DPG) has been found to be the product of the enzymatic degradation of cyclic 2,3-diphosphoglycerate (cDPG) in the archaebacterium Methanobacterium thermoautotrophicum delta H. Although 2,3-DPG has not previously been detected as a major soluble component of M. thermoautotrophicum, large pools accumulated at an incubation temperature of 50 degrees C (below the optimum growth temperature of 62 degrees C). Under these conditions, cellular activity was significantly decreased; a return of the culture to the optimum growth temperature restored the 2,3-DPG pool back to original low levels and caused steady-state cDPG levels to increase again. While 13CO2-pulse/12CO2-chase experiments at 50 degrees C showed that the cDPG turned over, the appearance of 2,3-DPG at NMR-visible concentrations required at least 10 h. Production of 2,3-DPG in vivo was prevented by exposure of the cells to O2. The enzyme responsible for this hydrolysis of cDPG was purified by affinity chromatography and appears to be a 33-kDa protein. Activity was detected in the presence of oxygen and was enhanced by a solution of 1 M KCl, 25 mM MgCl2, and dithiothreitol. Both Km and Vmax have been determined at 37 degrees C; kinetics also indicate that in vitro the product, 2,3-DPG, is an inhibitor of cDPG hydrolysis. These findings are discussed in view of a proposed role for cDPG in methanogens.     

Erythrocyte phosphofructokinase in rat strains with genetically determined differences in 2,3-diphosphoglycerate levels

We have studied the erythrocyte enzyme phosphofructokinase (PFK) from two strains of Long-Evans rats with genetically determined differences in erythrocyte 2,3-diphosphoglycerate (DPG) levels. The DPG difference is due to two alleles at one locus. With one probable exception, the genotype at this locus is always associated with the hemoglobin (Hb) electrophoretic phenotype, due to a polymorphism at the ^III-globin locus. The enzyme PFK has been implicated in the DPG difference because glycolytic intermediate levels suggest that this enzyme has a higher in vivo activity in High-DPG strain rats, although the total PFK activity does not differ. We report here that partially purified erythrocyte PFK from Low-DPG strain cells is inhibited significantly more at physiological levels of DPG (P<0.01) than PFK from High-DPG strain erythrocytes. Citrate and adenosine triphosphate also inhibit the Low-DPG enzyme more than the High-DPG enzyme. Therefore, a structurally different PFK, with a greater sensitivity to inhibitors, may explain the lower DPG and ATP levels observed in Low-DPG strain animals. These data support a two-locus (Hb and PFK) hypothesis and provide a gene marker to study the underlying genetic and physiologic relationships of these loci.This investigation was supported in part by Grant AM 14898, National Research Service Award 5 F 32 AM 05418, and Biochemical Research Support Grant 5 S07 RR 05551 from the National Institutes of Health.     

Effect of thyroxine on the hemoglobin affinity to oxygen and 2,3-diphosphoglycerate level in rat erythrocytes

Affinity of hemoglobin to oxygen was studied in rat erythrocytes under conditions of intraperitoneal administration of thyroxin in a dose of 0.4 mg per 100 g of animal weight each 24 h for five days. A significant right shift of the oxyhemoglobin dissociation curve is observed only on the 6th day simultaneously with the increase of the 2,3-diphosphoglycerate level in erythrocytes in the period under study. The results obtained from the study of the thyroxin effect on the respiratory function of hemoglobin permit recommending it as an antihypoxant.     

Diphosphoglycerate mutase and 2,3-diphosphoglycerate phosphatase activities of red cells: comparative electrophoretic study

Erythrocyte diphosphoglycerate mutase (EC 2.7.5.4.) and 2,3-diphosphoglycerate phosphatase (EC 3.1.3.13.) activities of normal human adults, and DPG mutase deficient subject as well as of several animal species were subjected to electrophoretic study on starch gel. In U.V. light 2,3-diphosphoglycerate phosphatase activity was revealed as a band of fluorescence decrease on a fluorescent background, by the oxydation of NADH, whereas diphosphoglycerate mutase appeared as a fluorescent zone. It was found that the electrophoretic pattern of both DPG mutase and 2,3-DPG phosphatase activities was different from one species to the other, but that, in each species, 2,3-DPG phosphatase activity showed the same electrophoretic pattern as DPG mutase activity.